Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission
about
Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission
description
im November 2015 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2015
@uk
name
Systemic inflammation and proi ...... ducing the length of remission
@en
Systemic inflammation and proi ...... ducing the length of remission
@nl
type
label
Systemic inflammation and proi ...... ducing the length of remission
@en
Systemic inflammation and proi ...... ducing the length of remission
@nl
prefLabel
Systemic inflammation and proi ...... ducing the length of remission
@en
Systemic inflammation and proi ...... ducing the length of remission
@nl
P50
P921
P356
P1476
Systemic inflammation and proi ...... ducing the length of remission
@en
P2093
H Oliveira
P304
P356
10.1111/BJD.14013
P407
P50
P577
2015-11-18T00:00:00Z